Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. More Details
Excellent balance sheet with high growth potential.
Share Price & News
How has Neuren Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NEU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NEU's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: NEU underperformed the Australian Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: NEU underperformed the Australian Market which returned 1.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Neuren Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StHow Much Of Neuren Pharmaceuticals Limited (ASX:NEU) Do Insiders Own?
3 months ago | Simply Wall StWho Has Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares?
5 months ago | Simply Wall StCan You Imagine How Neuren Pharmaceuticals' (ASX:NEU) Shareholders Feel About The 39% Share Price Increase?
Is Neuren Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NEU (A$1.19) is trading below our estimate of fair value (A$27.98)
Significantly Below Fair Value: NEU is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NEU is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: NEU is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NEU's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NEU is overvalued based on its PB Ratio (13.1x) compared to the AU Pharmaceuticals industry average (3.8x).
How is Neuren Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: NEU is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NEU's is expected to become profitable in the next 3 years.
Revenue vs Market: NEU's revenue (141.4% per year) is forecast to grow faster than the Australian market (5.1% per year).
High Growth Revenue: NEU's revenue (141.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEU is forecast to be unprofitable in 3 years.
How has Neuren Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEU is currently unprofitable.
Growing Profit Margin: NEU is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NEU is unprofitable, but has reduced losses over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare NEU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (44.2%).
Return on Equity
High ROE: NEU has a negative Return on Equity (-84.59%), as it is currently unprofitable.
How is Neuren Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: NEU's short term assets (A$9.7M) exceed its short term liabilities (A$601.0K).
Long Term Liabilities: NEU has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NEU is debt free.
Reducing Debt: NEU has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NEU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NEU has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Neuren Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEU's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEU's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Jonathan Charles Pilcher, also known as Jon, BSc (Hons), ACA had been a Company Secretary at Neuren Pharmaceuticals Limited since August 19, 2013 until August 01, 2020. Mr. Pilcher serves as Chief Exec...
|Chief Science Officer||16.92yrs||no data||no data|
|Chief Executive Officer||0.58yr||no data||no data|
|CFO & Company Secretary||0.33yr||no data||no data|
Experienced Management: NEU's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
|Independent Non-Executive Director||2.42yrs||AU$60.00k||no data|
|Independent Non-Executive Director||18.75yrs||AU$72.00k||3.13% |
|Independent Non-Executive Director||2.42yrs||AU$60.00k||0.017% |
|Independent Non-Executive Chairman||0.58yr||AU$60.00k||0.15% |
Experienced Board: NEU's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.4%.
Neuren Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: Neuren Pharmaceuticals Limited
- Ticker: NEU
- Exchange: ASX
- Founded: 1993
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$134.091m
- Shares outstanding: 114.61m
- Website: https://www.neurenpharma.com
Number of Employees
- Neuren Pharmaceuticals Limited
- 697 Burke Road
- Suite 201
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NEU||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Feb 2005|
|NURP.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Feb 2005|
|NEU||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Feb 2005|
|NEU||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Feb 2005|
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatm...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/03 07:04|
|End of Day Share Price||2020/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.